Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Status:
Recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
Low blood sugars are known to cause brain damage in newborn babies. One of the most common
causes of low blood sugars persisting beyond the new born period is a condition called
congenital hyperinsulinism (HI). This is a disease whereby the pancreas secretes too much
insulin and causes low blood sugars. Twenty to forty percent of these babies will have brain
damage. There are two forms of this disease. In one form only a small part of the pancreas
makes too much insulin (focal HI) and in the other, the whole pancreas make too much insulin
(diffuse HI). Another very similar disease is insulinoma which occurs after birth, but also
causes hyperinsulinism. If a surgeon could know which part of the pancreas has the focal
lesion he could remove it and cure the patient.
The purpose of this study is to investigate whether a new investigational drug called
Fluorodopa F 18, when used with a PET scan, can find the focal lesion and guide the surgeon
to remove it, thus curing the patient and preventing further brain damage.